TY - JOUR
T1 - DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1P29S mutation
AU - Tomino, Takahiro
AU - Tajiri, Hirotada
AU - Tatsuguchi, Takaaki
AU - Shirai, Takahiro
AU - Oisaki, Kounosuke
AU - Matsunaga, Shigeki
AU - Sanematsu, Fumiyuki
AU - Sakata, Daiji
AU - Yoshizumi, Tomoharu
AU - Maehara, Yoshihiko
AU - Kanai, Motomu
AU - Cote, Jean François
AU - Fukui, Yoshinori
AU - Uruno, Takehito
N1 - Funding Information:
We thank Ayumi Inayoshi, Arisa Aosaka, Linh Thi Hoai Nguyen, Nao Kanematsu, and Ai Uemura for technical assistance, and Hitoshi Aibara and Tetsuya Sakurai for critical reading of the manuscript. This study was supported by the Leading Advanced Projects for Medical Innovation (LEAP) from Japan Agency for Medical Research and Development (AMED) (to Y.F.; JP17gm0010001 ); the Platform Project for Supporting Drug Discovery and Life Science Research from AMED (to T.U.); and Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (to Y.F. and T.U.). Appendix A
Publisher Copyright:
© 2018 The Authors
PY - 2018/2/26
Y1 - 2018/2/26
N2 - Rac1 is a member of the Rho family of small GTPases that regulates cytoskeletal reorganization, membrane polarization, cell migration and proliferation. Recently, a self-activating mutation of Rac1, Rac1P29S, has been identified as a recurrent somatic mutation frequently found in sun-exposed melanomas, which possesses increased inherent GDP/GTP exchange activity and cell transforming ability. However, the role of cellular Rac1-interacting proteins in the transforming potential of Rac1P29S remains unclear. We found that the catalytic domain of DOCK1, a Rac-specific guanine nucleotide exchange factor (GEF) implicated in malignancy of a variety of cancers, can greatly accelerate the GDP/GTP exchange of Rac1P29S. Enforced expression of Rac1P29S induced matrix invasion and macropinocytosis in wild-type (WT) mouse embryonic fibroblasts (MEFs), but not in DOCK1-deficient MEFs. Consistently, a selective inhibitor of DOCK1 that blocks its GEF function suppressed the invasion and macropinocytosis in WT MEFs expressing Rac1P29S. Human melanoma IGR-1 and breast cancer MDA-MB-157 cells harbor Rac1P29S mutation and express DOCK1 endogenously. Genetic inactivation and pharmacological inhibition of DOCK1 suppressed their invasion and macropinocytosis. Taken together, these results indicate that DOCK1 is a critical regulator of the malignant phenotypes induced by Rac1P29S, and suggest that targeting DOCK1 might be an effective approach to treat cancers associated with Rac1P29S mutation.
AB - Rac1 is a member of the Rho family of small GTPases that regulates cytoskeletal reorganization, membrane polarization, cell migration and proliferation. Recently, a self-activating mutation of Rac1, Rac1P29S, has been identified as a recurrent somatic mutation frequently found in sun-exposed melanomas, which possesses increased inherent GDP/GTP exchange activity and cell transforming ability. However, the role of cellular Rac1-interacting proteins in the transforming potential of Rac1P29S remains unclear. We found that the catalytic domain of DOCK1, a Rac-specific guanine nucleotide exchange factor (GEF) implicated in malignancy of a variety of cancers, can greatly accelerate the GDP/GTP exchange of Rac1P29S. Enforced expression of Rac1P29S induced matrix invasion and macropinocytosis in wild-type (WT) mouse embryonic fibroblasts (MEFs), but not in DOCK1-deficient MEFs. Consistently, a selective inhibitor of DOCK1 that blocks its GEF function suppressed the invasion and macropinocytosis in WT MEFs expressing Rac1P29S. Human melanoma IGR-1 and breast cancer MDA-MB-157 cells harbor Rac1P29S mutation and express DOCK1 endogenously. Genetic inactivation and pharmacological inhibition of DOCK1 suppressed their invasion and macropinocytosis. Taken together, these results indicate that DOCK1 is a critical regulator of the malignant phenotypes induced by Rac1P29S, and suggest that targeting DOCK1 might be an effective approach to treat cancers associated with Rac1P29S mutation.
UR - http://www.scopus.com/inward/record.url?scp=85041958437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041958437&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2018.02.073
DO - 10.1016/j.bbrc.2018.02.073
M3 - Article
C2 - 29432733
AN - SCOPUS:85041958437
SN - 0006-291X
VL - 497
SP - 298
EP - 304
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -